PULM
PulmatrixยทNASDAQ
--
--(--)
--
--(--)
PULM Profile
Pulmatrix, Inc.
A clinical-stage biopharmaceutical company that developing innovative inhaled therapies to treat and prevent the spread of infectious and progressive respiratory diseases
945 Concord Street, Suite 1217, Framingham, MA 01701
--
Pulmatrix, Inc., incorporated in Nevada on January 18, 2013, is a wholly-owned subsidiary of Oculus Innovative Sciences, Inc. The Company is a clinical-stage biopharmaceutical company focused on the development of novel inhalation therapy products designed to prevent and treat respiratory and diseases with important unmet medical needs using the patented iSPERSE technology. The Company's proprietary product pipeline includes the treatment of central nervous system diseases such as acute migraine and severe lung diseases such as chronic obstructive pulmonary disease and allergic bronchopulmonary aspergillosis. The company's product candidates are based on the proprietary engineered dry powder delivery platform iSPERSE, which is designed to improve treatment delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes.
